Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC boosted its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 32.4% in the fourth quarter, HoldingsChannel reports. The firm owned 33,935 shares of the biopharmaceutical company’s stock after purchasing an additional 8,303 shares during the period. Intech Investment Management LLC’s holdings in Celldex Therapeutics were worth $858,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. EverSource Wealth Advisors LLC boosted its stake in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 878 shares during the last quarter. KBC Group NV boosted its stake in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 1,647 shares during the last quarter. AlphaQuest LLC grew its holdings in Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after acquiring an additional 2,705 shares in the last quarter. E Fund Management Co. Ltd. bought a new stake in shares of Celldex Therapeutics in the 4th quarter worth about $273,000. Finally, Point72 DIFC Ltd raised its stake in shares of Celldex Therapeutics by 101.7% in the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock valued at $480,000 after purchasing an additional 7,116 shares in the last quarter.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock opened at $19.64 on Monday. Celldex Therapeutics, Inc. has a one year low of $18.61 and a one year high of $47.00. The company has a 50-day simple moving average of $22.22 and a 200-day simple moving average of $27.02. The firm has a market capitalization of $1.30 billion, a P/E ratio of -7.64 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, sell-side analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, January 29th. The Goldman Sachs Group lowered their price target on Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Morgan Stanley assumed coverage on Celldex Therapeutics in a research note on Thursday. They set an “overweight” rating and a $46.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, UBS Group started coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They set a “buy” rating and a $44.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $54.33.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.